The period January to December 2015 and the fourth quarter 2015 in brief R&D expenses for the period amounted to SEK 20.4m (SEK 13.7m) of which the fourth quarter constituted SEK 8.3m (SEK 4.1m). Following EU’s approval of Kancera’s...
Read MoreThe period January to September 2015 and the third quarter 2015 in brief R&D expenses for the period amounted to SEK 12.1m (SEK 9.6m) of which the third quarter constituted SEK 3.2m (SEK 2.7m). Operating income for the period...
Read MoreThe period January to June 2014 and the second quarter 2015 in brief R&D expenses for the period amounted to SEK 8.8m (SEK 6.9m) of which the second quarter constituted SEK 4.6m (SEK 3.4m). Operating income for the period...
Read MoreIn 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....
Read MoreIn 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....
Read MoreJanuary 1 - September 30, 2014. All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. In connection with this Kancera...
Read MoreJanuary 1 - June 30, 2014 All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. In connection with this Kancera...
Read MoreAll figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read MoreAll figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read MoreAll figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read More